DBV Technologies S.A. (DBVT)
Stock Price:
$2.40 USD
-1.71 (-41.59%)
Updated Aug 4, 2020 11:35 AM EDT - Market open
Key Info
| Market Cap |
262.93M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-172.57M |
| Shares Out |
109.75M |
| EPS (ttm) |
-3.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$2.40 |
| Previous Close |
$4.10 |
| Change ($) |
-1.71 |
| Change (%) |
-41.59% |
| Day's Open |
2.58 |
| Day's Range |
2.32 - 2.60 |
| Day's Volume |
3,895,120 |
| 52-Week Range |
2.02 - 13.49 |
More Stats
| Market Cap |
262.93M |
| Enterprise Value |
96.78M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
109.75M |
| Float |
35.99M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-3.27 |
| FCF / Share |
-4.97 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.79M |
| Short Ratio |
9.02 |
| Short % of Float |
n/a |
| Beta |
2.01 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
2.10 |
| Revenue |
n/a |
| Operating Income |
-185.21M |
| Net Income |
-172.57M |
| Free Cash Flow |
-150.02M |
| Net Cash |
166.14M |
| Net Cash / Share |
1.52 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-35.72% |
| ROE |
-94.15% |
| ROIC |
-568.10% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
6 |
| Overweight |
0 |
| Hold |
4 |
| Underweight |
1 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$10.78*
(350.04% upside)
Low
2.98
Current: $2.40
High
28.76
Target: 10.78
*Average 12-month USD price target from 11 stock analysts.
Financial Performance
Financial numbers in millions EUR.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | - | - | - | - | 0.20 | 0.21 | 0.18 | 0.17 |
| Revenue Growth | - | - | - | - | -4.27% | 15.93% | 4.38% | - |
| Gross Profit | - | - | - | - | 0.07 | 0.08 | 0.08 | 0.09 |
| Operating Income | -165 | -181 | -157 | -125 | -51.51 | -29.19 | -23.60 | -16.01 |
| Net Income | -154 | -166 | -148 | -115 | -44.67 | -24.01 | -19.31 | -12.91 |
| Shares Outstanding | 30.16 | 24.99 | 24.65 | 24.21 | 19.16 | 19.16 | - | - |
| Earnings Per Share | -4.15 | -5.74 | -5.97 | -4.68 | -2.08 | -1.49 | -1.42 | -1.05 |
| Operating Cash Flow | -129 | -137 | -114 | -59.54 | -26.76 | -20.56 | -13.25 | -10.43 |
| Capital Expenditures | -5.00 | -4.75 | -7.55 | -8.21 | -4.51 | -0.97 | -1.17 | -0.36 |
| Free Cash Flow | -134 | -141 | -122 | -67.75 | -31.27 | -21.53 | -14.42 | -10.79 |
| Cash & Equivalents | 172 | 123 | 138 | 256 | 323 | 115 | 39.40 | 38.35 |
| Total Debt | 24.16 | 2.48 | 4.15 | 4.64 | 4.84 | 4.13 | 1.44 | 1.15 |
| Net Cash / Debt | 148 | 120 | 134 | 252 | 319 | 110 | 37.96 | 37.19 |
| Assets | 241 | 172 | 178 | 288 | 343 | 125 | 46.24 | 42.97 |
| Liabilities | 69.91 | 50.46 | 47.88 | 44.65 | 21.20 | 9.97 | 5.84 | 3.80 |
| Book Value | 172 | 121 | 130 | 243 | 322 | 115 | 40.40 | 39.17 |
Numbers in millions EUR, except per-share numbers.
Company Details
| Full Name |
DBV Technologies S.A. |
| Country |
France |
| Employees |
311 |
| CEO |
Daniel Tassé |
Stock Information
| Ticker Symbol |
DBVT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: DBVT |
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.